Group 1 - The innovative drug sector has led a strong rebound in the pharmaceutical industry after a prolonged adjustment period, attracting increased market attention and driving the issuance of related thematic funds [1] - Multiple public fund institutions, including浦银安盛基金, 鹏华基金, 招商基金, and 长城基金, have recently filed for medical thematic funds, indicating a growing interest in the sector [1] - As of the report, several medical thematic funds have already entered the issuance phase, including 易方达恒生港股通创新药交易型开放式指数证券投资基金 and 大成恒生医疗保健交易型开放式指数证券投资基金 [1] Group 2 - The pace from fund issuance to establishment has noticeably accelerated, with some funds, such as those from 东方阿尔法基金 and 平安基金, announcing early closure of fundraising [2] - Early closure of fundraising is likely aimed at seizing the current rapid rise in the pharmaceutical sector, allowing funds to enter the market more quickly and potentially achieve better performance [2] - Long城基金's fund manager highlighted that the innovative drug sector has outperformed the pharmaceutical industry this year, driven by a solid fundamental backdrop within the broader "technology bull" market [2] Group 3 - The fundamental reasons for the rise in the innovative drug sector include a prolonged adjustment period from 2021 to 2024, leading to significantly low valuations, particularly in the Hong Kong market [2] - The trend of China's innovative drug industry is upward, with a shift from rapid follow-up to global innovation in drug development, and a notable increase in Chinese companies' overseas licensing since 2020 [2] - Domestic policies are supportive of the innovative drug industry, laying a solid foundation for its long-term development [2] Group 4 - Compared to overseas counterparts, Chinese innovative drug companies have achieved "curve overtaking" in certain areas, with a clear trend of "going global" that is strengthening [3] - There is optimism regarding the explosive growth potential of Chinese innovative drug companies in the future, with positive expectations for their industry and stock price trends [3]